Staff Writer

Balderton sets smaller fund for earlier stage deals

U.S.-style VC ecosystem develops in several cities in Europe

More firms weigh IPOs as biotech fever reaches Europe

With the IPO window nudging open, despite recent setbacks in the broader public markets worldwide, venture-backed companies that in the past might have opted for a trade sale to larger pharmaceutical companies are considering a share listing

David C. Turner, Guardian Life’s PE architect, to step down next month: UPDATED

Managing Director Maurice Gordon will take over for Turner, who departs effective May 30.

March madness: Largest number of VC-backed IPOs in 13 years

Details on the 18 VC-backed companies that went public on U.S. exchanges in March: 2U, A10 Networks, Achaogen, Aerohive Networks, Akebia Therapeutics, Amber Road, Applied Genetic Technologies, Aquinox Pharmaceuticals, Borderfree, Castlight Health, Coupons.com, Everyday Health, King Digital Entertainment, Mediwound, Paylocity, Q2 Holdings, Recro Pharma and Versartis.

IPO Profile: Aquinox Pharmaceuticals Inc

Augment Investments, B.C. Advantage Fund, Baker Brothers, Johnson & Johnson, Pfizer and Ventures West Capital collectively own 6,606,261 shares worth about $73 million at the IPO price.

IPO Profile: Applied Genetic Technologies Corp

Alta Partners, Intersouth Partners, InterWest Partners, Medimmune, Osage Partners and Sr One collectively hold 9,123,707 shares worth about $109 million at the IPO price.

IPO Profile: Amber Road Inc

Cross Atlantic Capital, Goldman, Sachs, NJTC Investment Fund, Orix Venture Finance and Updata Partners collectively own 12.4 million shares worth $161 million at the IPO price.

IPO Profile: Achaogen Inc

5AM Ventures, ARCH Venture Partners, Domain Partners, Omega Funds, Venrock, Versant Ventures and Wellcome Trust collectively own 9.5 million shares worth $114 million at the IPO price.

IPO Profile: A10 Networks Inc

Summit Partners, Mitsui, Enspire Capital, Harbinger Venture Management and others collectively own 17.8 million shares worth about $267 million at the IPO price.

IPO Profile: 2U Inc

Bessemer Venture Partners, Highland Capital Partners Novak Biddle Venture Partners and Redpoint Ventures collectively hold 16.79 million shares worth $218.2 million at the IPO price.